Treatments and trials for osteosarcoma
A collection of drugs and clinical trials relevant to osteosarcoma, a type of bone cancer that most often affects children, teenagers and young adults. Each entry links to its original source so you can read more.
Dedication
A great thanks to the good people of UCLH and the London Sarcoma Service, with Dr Beatrice Seddon as lead osteosarcoma consultant; the Royal National Orthopaedic Hospital, Stanmore, with Professor Briggs; the Royal Brompton with Mr Jordan; the whole team, including nursing and research, from porters to consultants; and the Macmillan nurses.
Research entries
How we rate "How well did it work?"
Every entry gets one of five levels. The level is set by fixed rules applied to the facts recorded for each entry, not by personal opinion. It describes what the evidence in our notes shows for osteosarcoma only. It is not a recommendation.
Entries with no development phase recorded, such as registries and observational studies, are always shown as level 5, Too early to tell, unless they are approved. Levels 2 and 3 apply only to phased trials.
Rules are applied in order: 1) phase Approved and status Approved/marketed; 5) preclinical, recruiting or not yet recruiting, or the entry says there are no results; 4) the entry describes a negative result (for example "did not", "not statistically significant"); 2) phase 3 with a positive result; 3) any other trial with a positive result; otherwise 5.
Filters
Five-year survival over time, 1950 to 2026
This chart shows the share of people with osteosarcoma who were alive five years after diagnosis, in different eras. It shows overall survival, and where reported, survival for cancer that had not spread (localised) and had spread (metastatic). Gaps mean no figure was recorded.
Before you look: this chart shows survival figures over time. The numbers describe large groups of people in the past, not any one person, and treatment has changed since.
Show the chart as a table (text version)
| Era | Overall | Localised | Metastatic | Status |
|---|
Please note: these figures come from different studies, countries and age groups, so they are not directly comparable. They describe groups of people, not any one person's outlook.
Sources
Comparing regions
About this portal and its owner
In 2006, at 23 years old, I was diagnosed with high-grade osteosarcoma. I was in my first job, with the world ahead of me. The tumour was at the top of the humerus in my right arm, and after two unsuccessful cycles of chemotherapy it had grown into my shoulder blade. I was moved onto a different set of drugs, but by then it was too late, and I needed a right forequarter amputation. My treatment was extended for 10 months, after which I had a series of five lung and chest operations. Six years after I started my first chemotherapy, I had to go through the whole thing again for another year, finishing in the summer of the London 2012 Olympics. When I left the care of the London Sarcoma Service at University College London Hospital, I had so many files of paperwork to my name that they had to be wheeled around on a trolley.
I’ve been cancer-free ever since. I’ve led a full life, and I’m now happily married with two lovely daughters. I built this portal to thank all the amazing doctors, nurses, surgeons and researchers, the entire healthcare teams at UCLH, the Royal Brompton and the Royal National Orthopaedic Hospital, Stanmore, and my family.
I started this portal to gather research on osteosarcoma treatments in one place and to explain it in plain English, for patients, families and anyone curious.
Each entry is checked against a published source, such as a medical journal, a trial registry or a medicines regulator, and the source is linked on every card. I am not a doctor, and this portal does not recommend any treatment.
Glossary
- Clinical trial
- A carefully planned research study in people, to find out whether a treatment is safe and whether it works.
- Phase
- Trials happen in stages. Phase 1 mainly tests safety and dose in a small group. Phase 2 looks at whether the treatment works for a particular cancer. Phase 3 compares it with the current standard treatment in a larger group.
- Approval
- When a medicines regulator, such as the European Medicines Agency (EMA) or the UK's MHRA, agrees a medicine can be used for a specific condition. Approval in one region does not mean approval everywhere.
- Placebo
- A dummy treatment with no active medicine, used so researchers can compare results fairly.
Questions and feedback
Spotted a mistake, or know of a trial or drug that should be listed? Send a short text message below. Text only: no files, attachments or images can be sent, links are stored as plain text, and messages are never shown on this site. For questions about your own care, please speak to your medical team.